Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

DECEMBER 05, 2012
Ben Leach
Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.

Copyright© MD Magazine 2006-2017 Intellisphere, LLC. All Rights Reserved.